Slide 1: Q1 2026 Business Update
Nasdaq: PAVM Q1 2026 Business Update May 15, 2026 LISHAN AKLOG, MD Chairman & CEO DENNIS MCGRATH President & CFO
Slide 2: Disclaimer
Disclaimer ▪ This presentation may contain certain forward-looking statements related to PAVmed Inc. or Lucid Diagnostics Inc. (the “Companies”) that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements
Slide 3: Lishan Aklog, M.D., Chairman & CEO
Nasdaq: PAVM Lishan Aklog, M.D. Chairman & CEO
Slide 4: PAVmed Corporate Structure
PAVmed Corporate Structure Nasdaq: PAVM D IAGNOSTIC S D I G I T A L H E A L T H Medical Device Portfolio Nasdaq: LUCD Privately Held Privately Held Digital Cancer Care Platform & Smart Vascular Access Incubator for MedTech Technologies, including PortIO Early Detection of Esophageal Precancer Port a
Slide 5: Recent Highlights
Recent Highlights Veris Health ▪ Commercial phase of OSU strategic engagement well underway ▪ Clinical rollout to expand to additional departments ▪ EHR integration working well ▪ Implantable physiological monitor development progressing toward planned end of 2026 FDA 510(k) submission ▪ Partnership
Slide 6: Q1 2026 Financial Update
Nasdaq: PAVM Q1 2026 Financial Update
Slide 7: Balance Sheet
Balance Sheet ($ in thousands) 1Q26 4Q25 Change Assets Cash $6,460 $1,538 $4,922 Equity Method Investments (Lucid) $35,998 $34,120 $1,878 All other Assets $2,961 $3,154 $(193) Liabilities Accounts Payable $983 $678 $305 Senior Secured Convertible Notes $14,900 $11,100 $3,800 Other Liabilities $4,548
Slide 8: P&L
P&L ($ in thousands) 1Q26 1Q25 Change Revenue + Management Fee Income $3,178 $3,158 $20 Operating Expenses $8,057 $5,454 $2,603 Net Income (Loss) $(1,064) $18,623 $(19,687) EBITDA $(307) $19,007 $(19,314) Stock-Based Compensation $182 $930 $(748) Non-GAAP Adjusted Loss $(1,851) $(910) $(941) Non-GAA
Slide 9: Non-GAAP Operating Expense
Non-GAAP Operating Expense 8,000 7,000 6,000 6,253 5,904 5,000 4,431 4,484 4,392 4,000 3,000 2,000 1,000 0 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Cost of Revenue Sales and Marketing General & Admin R&D Total To supplement our unaudited financial results presented in accordance with U.S. generally a
Slide 10: Q&A
XK PAVmed Nasdaq: PAVM 2 a: Q&A
Slide 11: Closing Remarks
Nasdaq: PAVM Closing Remarks